High D-dimer plasma levels correlated with risk scores in patients on antiplatelets (driven by CHA2DS2-VASc ≥5) and were associated with in-hospital mortality.
Observational
Does plasma D-dimer level serve as a subclinical marker of thrombotic risk and mortality in elderly patients with atrial fibrillation?
Plasma D-dimer levels may serve as a useful subclinical marker to refine thromboembolic risk prognosis and guide antithrombotic therapy in elderly patients with atrial fibrillation.
Aged patients with atrial fibrillation (AF) are at high risk of both thromboembolic and haemorrhagic complications of disease and of its treatment. A study was provided to assess the role of D-dimer plasma level as a marker of thrombosis in aged patients with AF having no clinical signs of active thrombosis depending on used treatment strategy and quantitative thrombotic and haemorrhagic risk of AF. The results show that D-dimer plasma levels correlate with scores of thromboembolic and haemorrhagic risks in group on antiplatelet agents but not anticoagulants, with the difference in D-dimer level driven by subgroup on CHA2DS2-VASc score ≥5. High D-dimer level was associated with in-hospital mortality and rhythm of AF at the moment of blood sample collection. Therefore, an accuracy of risk prognosis of fatal complications of AF for elderly patients may be increased by using the laboratory markers of thrombus formation such as D-dimer and by using the obtained results to guide an antithrombotic therapy.
Zadvorev et al. (Wed,) conducted a observational in Atrial Fibrillation. D-dimer plasma level was evaluated on Correlation with thromboembolic and haemorrhagic risk scores and in-hospital mortality. High D-dimer plasma levels correlated with risk scores in patients on antiplatelets (driven by CHA2DS2-VASc ≥5) and were associated with in-hospital mortality.